Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:ONC)

234.78 +1.41 (+0.60%)
Streaming Delayed Price Updated: 12:56 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BeiGene, Ltd. - American Depositary Shares

Earnings Scheduled For May 14, 2025
Via Benzinga
Earnings Preview: BeiGene
Via Benzinga
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance. 
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
Forecasting The Future: 4 Analyst Projections For BeiGene
Via Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later. 
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans. 
Via Benzinga
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment. 
Via Benzinga
Earnings Scheduled For March 7, 2025
Via Benzinga
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1-positive patients. 
Via Benzinga
Exposures Product Safety
Alibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: Unity, Super Micro Computer, Alibaba, FTAI Aviation, STMicroelectronics, XPeng, Analog Devices, BeiGene, Tencent Music, Microchip Technology. 
Via Benzinga
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer 
Via Stocktwits
Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes
Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer. Gastric cancer studies end due to lack of PFS benefit. 
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS